BioavailabilityNCT05840848
Effect of Iron and Zinc Supplementation on B-carotene Bioavailability in Healthy Males
A study of Bioavailability, run by University of Hohenheim at 1 site in Germany.
Trial summary
In vitro studies found supplemental levels of iron and zinc to inhibit the micellization and cellular uptake of β-carotene. Here, we investigated this in vivo, in a double-blind 3-arm crossover human trial. Read more about this study
- Who is it for?
- Ages 18 to 50 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Bioavailability
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 12 participants
- Where
- 1 siteGermany
- Study dates
- 21 Nov 2017to 1 Jun 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Male
- aged 18 and 50 years
Who cannot join
- overweight (BMI >25 kg/m2),
- metabolic and endocrine diseases,
- drug abuse,
- use of dietary supplements,
- us of any form of medication,
- smoking,
Show all 11Show fewer
- frequent alcohol consumption (>20 g ethanol/day),
- adherence to a restrictive dietary regimen,
- physical activity of more than 5 h/wk,
- participation in a clinical trial within the past 3 months prior to recruitment,
- a known intolerance against β-carotene, iron and/or zinc supplements.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect of Simultaneously Consuming Iron and Zinc Supplements With That of B-carotene, on the B-carotene Bioavailability in Healthy Males
In vitro studies found supplemental levels of iron and zinc to inhibit the micellization and cellular uptake of β-carotene. Here, we investigated this in vivo, in a double-blind 3-arm crossover human trial.
Healthy males (n=6) ingested, with breakfast, a single dose of 15 mg β-carotene in combination with either a placebo, 25 mg iron or 30 mg zinc capsule. Blood samples were collected at baseline and hourly for 10 hours. The triacylglycerol-rich fraction (TRF) was analysed for concentrations of β-carotene and plasma for β-carotene, retinol, triacylglycerols, LDL- and HDL-cholesterol.
Read the detailed description
The study followed a double-blind crossover design with three study arms separated by one week washout periods. In short, the participants were asked to follow a diet low in carotenoids by avoiding all orange, yellow, red and green fruits and vegetables for four days. This was followed by three days of a strictly carotenoid-free diet, which only allowed foods from a specified list (Supplemental Table A2). On each study day, β-carotene was administered in the morning after a >10 hour overnight fast (Supplemental Figure A1). All participants orally ingested, in random order, a single dose of 15 mg β-carotene (BIOVEA) with either a placebo (empty capsule), 25 mg iron (FeSO4; Woerwag Pharma GmbH \& Co. KG, Boeblingen, Germany) or 30 mg zinc (ZnSO4; Woerwag Pharma) capsule. A standardised dinner was provided on the evening before the trial and standardised meals were provided during the entire intervention day (Supplemental Table A3). On the first study day, the amount of food (weight or volume) consumed by each participant for each meal was recorded and the same amounts provided during the following two arms to ensure similar food consumption, especially of fat. Water was available unrestricted for consumption throughout the day. Blood samples were drawn from an indwelling venous cannula and collected at 0 hours directly before β-carotene supplementation and then every hour for 10 hours.
For the determination of plasma concentrations of β-carotene, LDL- and HDL-cholesterol, and triacylglycerols (TAG), blood was collected in tubes containing EDTA (Sarstedt AG \& Co, Nuebrecht, Germany) and immediately centrifuged (3000 × g, 10 min, 4 °C). From the obtained plasma samples, three aliquots were stored at -80 °C until further analysis and the rest ultracentrifuged to obtain the triacylglycerol-rich fraction (TRF). For the analyses of liver and kidney function markers, plasma and serum were obtained from blood sampled at the 0- and 4-hour time points.
The TRF was prepared according to [10]. Briefly, plasma (3.5 mL) was transferred to an ultracentrifuge tube and carefully overlaid with 8 mL 1.3% sodium chloride and then ultracentrifuged (Beckman Coulter, OptimaTM L-80 XP Ultracentrifuge) using a swinging bucket rotor (SW41Ti) at 150 000 x g for 1 hour at 4 °C. Afterwards, the TRF was isolated by transferring the upper ~6 mL, which was then overlaid with nitrogen gas to minimize oxidation and stored at -80 °C until extraction.
The plasma samples were randomly extracted and analysed by HPLC according to [15]. Briefly, 40 µL plasma was extracted with an ethanol/n-butanol mixture (50:50) containing apo-80-carotenal-methyloxime (12µL/100 mL; Fluka Analytical (Merck Group KGaA), Darmstadt, Germany) as internal standard. After centrifugation, the clear supernatant was analysed by HPLC.
The TRF was extracted and analysed by HPLC [15]. For the extraction, 100 µl apo-80-carotenal-methyloxime (12 µL/100 mL) and 2 mL ethanol (for deproteination) were added to 3 mL of the TRF and vortexed for 30 sec. The solution was extracted twice with 2 mL hexane. The hexane layers were removed, combined and evaporated in a centrifugal vacuum concentrator (Christ, RVC 2-25 CD plus) and the dried sample re-dissolved in 100 µL acetonitrile and immediately analysed by HPLC.
Both the plasma and TRF samples were analysed using a Shimadzu HPLC (LC-10AD) equipped with a UV-Vis detector (SPD 20A, set at 450 nm). Carotenoids were separated using a ReproSil 80 ODS-2 column (3 µm, 250 x 4.6 mm; Dr. Maisch GmbH, Ammerbuch, Germany) and an eluent in recirculation mode (82% acetonitrile, 15% 1,4-dioxin, and 3% methanol (vol/vol) containing 100 mM ammonium acetate and 10 mM triethylamine) at a flow rate of 1.5 mL/min [15]. A β-carotene standard (≥97.0% purity, Sigma-Aldrich) was used to construct a standard curve.
Plasma TAG, HDL- and LDL-cholesterol were analysed by a clinical laboratory (Laborärzte Sindelfingen, Sindelfingen, Germany).
- Conditions
- Bioavailability
- Being tested
- Control beta-carotene supplement plus Placebo, Control beta-carotene supplement plus iron Supplement, Control beta-carotene supplement plus zinc Supplement
- Keywords
- B-carotene, Iron, zinc, Supplements
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Control beta-carotene supplement plus PlaceboDietary supplement
15 mg beta-carotene supplement from BIOVEA consumed before breakfast together with an empty capsule.
Control beta-carotene supplement plus iron SupplementDietary supplement
15 mg Beta-carotene supplement from BIOVEA consumed before breakfast together with 25 mg iron (FeSO4; Woerwag Pharma GmbH \& Co. KG, Boeblingen, Germany)
Control beta-carotene supplement plus zinc SupplementDietary supplement
15 mg Beta-carotene supplement from BIOVEA consumed before breakfast together with 30 mg zinc (ZnSO4; Woerwag Pharma GmbH \& Co. KG, Boeblingen, Germany)
| Study group | Role | What they receive |
|---|---|---|
| Control plus Placebo | Active comparator | B-carotene supplement (15 mg) consumed in the morning after a >10 hour overnight fast. Receives: Dietary Supplement: Control beta-carotene supplement plus Placebo |
| Control plus iron Supplement | Experimental | B-carotene supplement (15 mg) and iron sulphate supplement (25 mg) consumed in the morning after a >10 hour overnight fast. Receives: Dietary Supplement: Control beta-carotene supplement plus iron Supplement |
| Control plus zinc Supplement | Experimental | B-carotene supplement (15 mg) and zinc sulphate supplement (30 mg) consumed in the morning after a >10 hour overnight fast. Receives: Dietary Supplement: Control beta-carotene supplement plus zinc Supplement |
What is being measured
The primary outcome is the main question the study is designed to answer.
TRF B-carotene
B-carotene concentration in the triacylglycerol-rich fraction of the plasma
Measured: 10 hours
Plasma B-carotene
B-carotene concentration int he plasma
Measured: 10 hours
Secondary outcomes (5)
Plasma LDL-cholesterol
LDL-cholesterol concentration in Plasma
Measured: 10 hours
Plasma HDL-cholesterol
HDL-cholesterol concentration in Plasma
Measured: 10 hours
Plasma TAG
triacylglycerol concentration in Plasma
Measured: 10 hours
liver function markers
γ-GT, AST, ALT, Alkaline phosphatase and Bilirubin measured
Measured: 4 hours
Kidney funtion markers
Creatinine i.S. and Uric acid measured
Measured: 4 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 May 2023
- Study start21 Nov 2017
- Primary completion14 Dec 2017
- Study completion1 Jun 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for BioavailabilityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Crossover
- Model description
- double-blind crossover
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 12 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Hohenheim
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Johanita Kruger, University of Hohenheim
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05840848
- Sponsor's protocol ID
- AZ: F-2017-039
- Status last verified
- May 2023
- First submitted
- 28 Mar 2023
- Last updated
- 6 May 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Kruger J, Sus N, Moser A, Scholz S, Adler G, Venturelli S, Frank J. Low beta-carotene bioaccessibility and bioavailability from high fat, dairy-based meal. Eur J Nutr. 2024 Sep;63(6):2261-2270. doi: 10.1007/s00394-024-03423-w. Epub 2024 May 16.
PubMed 38753174
Study at a glance
From the registry record, last updated by the sponsor on 6 May 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Simultaneously Consuming Iron and Zinc Supplements With That of B-carotene, on the B-carotene Bioavailability in Healthy Males
- ClinicalTrials.gov ID
- NCT05840848
- Acronym / sponsor ID
- AZ: F-2017-039
- Conditions
- Bioavailability
- Keywords
- B-carotene, Iron, zinc, Supplements
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 12 participants (actual)
- Lead sponsor
- University of HohenheimUniversity, hospital or other
- Study start
- 21 Nov 2017 (actual)
- Primary completion
- 14 Dec 2017 (actual)
- Study completion
- 1 Jun 2018 (actual)
- First posted
- 3 May 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In vitro studies found supplemental levels of iron and zinc to inhibit the micellization and cellular uptake of β-carotene. Here, we investigated this in vivo, in a double-blind 3-arm crossover human trial.
Healthy males (n=6) ingested, with breakfast, a single dose of 15 mg β-carotene in combination with either a placebo, 25 mg iron or 30 mg zinc capsule. Blood samples were collected at baseline and hourly for 10 hours. The triacylglycerol-rich fraction (TRF) was analysed for concentrations of β-carotene and plasma for β-carotene, retinol, triacylglycerols, LDL- and HDL-cholesterol.
Detailed description
The study followed a double-blind crossover design with three study arms separated by one week washout periods. In short, the participants were asked to follow a diet low in carotenoids by avoiding all orange, yellow, red and green fruits and vegetables for four days. This was followed by three days of a strictly carotenoid-free diet, which only allowed foods from a specified list (Supplemental Table A2). On each study day, β-carotene was administered in the morning after a >10 hour overnight fast (Supplemental Figure A1). All participants orally ingested, in random order, a single dose of 15 mg β-carotene (BIOVEA) with either a placebo (empty capsule), 25 mg iron (FeSO4; Woerwag Pharma GmbH \& Co. KG, Boeblingen, Germany) or 30 mg zinc (ZnSO4; Woerwag Pharma) capsule. A standardised dinner was provided on the evening before the trial and standardised meals were provided during the entire intervention day (Supplemental Table A3). On the first study day, the amount of food (weight or volume) consumed by each participant for each meal was recorded and the same amounts provided during the following two arms to ensure similar food consumption, especially of fat. Water was available unrestricted for consumption throughout the day. Blood samples were drawn from an indwelling venous cannula and collected at 0 hours directly before β-carotene supplementation and then every hour for 10 hours.
For the determination of plasma concentrations of β-carotene, LDL- and HDL-cholesterol, and triacylglycerols (TAG), blood was collected in tubes containing EDTA (Sarstedt AG \& Co, Nuebrecht, Germany) and immediately centrifuged (3000 × g, 10 min, 4 °C). From the obtained plasma samples, three aliquots were stored at -80 °C until further analysis and the rest ultracentrifuged to obtain the triacylglycerol-rich fraction (TRF). For the analyses of liver and kidney function markers, plasma and serum were obtained from blood sampled at the 0- and 4-hour time points.
The TRF was prepared according to [10]. Briefly, plasma (3.5 mL) was transferred to an ultracentrifuge tube and carefully overlaid with 8 mL 1.3% sodium chloride and then ultracentrifuged (Beckman Coulter, OptimaTM L-80 XP Ultracentrifuge) using a swinging bucket rotor (SW41Ti) at 150 000 x g for 1 hour at 4 °C. Afterwards, the TRF was isolated by transferring the upper ~6 mL, which was then overlaid with nitrogen gas to minimize oxidation and stored at -80 °C until extraction.
The plasma samples were randomly extracted and analysed by HPLC according to [15]. Briefly, 40 µL plasma was extracted with an ethanol/n-butanol mixture (50:50) containing apo-80-carotenal-methyloxime (12µL/100 mL; Fluka Analytical (Merck Group KGaA), Darmstadt, Germany) as internal standard. After centrifugation, the clear supernatant was analysed by HPLC.
The TRF was extracted and analysed by HPLC [15]. For the extraction, 100 µl apo-80-carotenal-methyloxime (12 µL/100 mL) and 2 mL ethanol (for deproteination) were added to 3 mL of the TRF and vortexed for 30 sec. The solution was extracted twice with 2 mL hexane. The hexane layers were removed, combined and evaporated in a centrifugal vacuum concentrator (Christ, RVC 2-25 CD plus) and the dried sample re-dissolved in 100 µL acetonitrile and immediately analysed by HPLC.
Both the plasma and TRF samples were analysed using a Shimadzu HPLC (LC-10AD) equipped with a UV-Vis detector (SPD 20A, set at 450 nm). Carotenoids were separated using a ReproSil 80 ODS-2 column (3 µm, 250 x 4.6 mm; Dr. Maisch GmbH, Ammerbuch, Germany) and an eluent in recirculation mode (82% acetonitrile, 15% 1,4-dioxin, and 3% methanol (vol/vol) containing 100 mM ammonium acetate and 10 mM triethylamine) at a flow rate of 1.5 mL/min [15]. A β-carotene standard (≥97.0% purity, Sigma-Aldrich) was used to construct a standard curve.
Plasma TAG, HDL- and LDL-cholesterol were analysed by a clinical laboratory (Laborärzte Sindelfingen, Sindelfingen, Germany).
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
- Model description
- double-blind crossover
| Arm | Type | Receives |
|---|---|---|
| Control plus Placebo | Active comparator | Dietary Supplement: Control beta-carotene supplement plus PlaceboB-carotene supplement (15 mg) consumed in the morning after a >10 hour overnight fast. |
| Control plus iron Supplement | Experimental | Dietary Supplement: Control beta-carotene supplement plus iron SupplementB-carotene supplement (15 mg) and iron sulphate supplement (25 mg) consumed in the morning after a >10 hour overnight fast. |
| Control plus zinc Supplement | Experimental | Dietary Supplement: Control beta-carotene supplement plus zinc SupplementB-carotene supplement (15 mg) and zinc sulphate supplement (30 mg) consumed in the morning after a >10 hour overnight fast. |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Male
- aged 18 and 50 years
Key exclusion criteria (11 listed)
- overweight (BMI >25 kg/m2),
- metabolic and endocrine diseases,
- drug abuse,
- use of dietary supplements,
- us of any form of medication,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Control beta-carotene supplement plus Placebo15 mg beta-carotene supplement from BIOVEA consumed before breakfast together with an empty capsule. | Dietary supplement | Control plus Placebo |
| Control beta-carotene supplement plus iron Supplement15 mg Beta-carotene supplement from BIOVEA consumed before breakfast together with 25 mg iron (FeSO4; Woerwag Pharma GmbH \& Co. KG, Boeblingen, Germany) | Dietary supplement | Control plus iron Supplement |
| Control beta-carotene supplement plus zinc Supplement15 mg Beta-carotene supplement from BIOVEA consumed before breakfast together with 30 mg zinc (ZnSO4; Woerwag Pharma GmbH \& Co. KG, Boeblingen, Germany) | Dietary supplement | Control plus zinc Supplement |
Primary outcome
TRF B-carotene
Time frame: 10 hours
B-carotene concentration in the triacylglycerol-rich fraction of the plasma
Plasma B-carotene
Time frame: 10 hours
B-carotene concentration int he plasma
5 secondary outcomes
Plasma LDL-cholesterol
Time frame: 10 hours
Plasma HDL-cholesterol
Time frame: 10 hours
Plasma TAG
Time frame: 10 hours
liver function markers
Time frame: 4 hours
Kidney funtion markers
Time frame: 4 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 May 2023.
- Derived from this study: PubMed 38753174Kruger J, Sus N, Moser A, Scholz S, Adler G, Venturelli S, Frank J. Low beta-carotene bioaccessibility and bioavailability from high fat, dairy-based meal. Eur J Nutr. 2024 Sep;63(6):2261-2270. doi: 10.1007/s00394-024-03423-w. Epub 2024 May 16.
Related trials for Bioavailability
Not yet recruitingPhase 1
Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple Doses
Obesity, Overweight
Not yet recruitingPhase 1
Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants
Healthy Adult Participants
Active, not recruitingPhase 1
A Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283
Asthma
Not yet recruitingPhase 1
A Study of Imlunestrant (LY3484356) in Healthy Female Participants
Healthy
Active, not recruitingPhase 4
Tacrolimus C:D Ratio Measured in Renal Transplant Recipients Treated With Once-daily Prolonged-release Drugs
Immunosuppression
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study of Bioavailability, run by University of Hohenheim at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 May 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
TRF B-carotene (time frame: 10 hours). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05840848, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2023.